Home›Clinical trials›A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

A study testing whether a GLP-1 medicine from Novo Nordisk, semaglutide, can help with weight.

Who can join
Adults 18+, have obesity, BMI 30+.
What you take
semaglutide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
How long it lasts
The study runs about 13 months.
What you get
The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
Phase Phase 2Sponsor Novo Nordisk A/SDrug semaglutideClass GLP-1 RASites 24 USEnrollment target 230

What this study is for

Primary condition: Obesity.

Full scientific study title: A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity.

Who can join

Age18 and upSexAnyBMI30 or higher

Adults 18+, have obesity, BMI 30+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Male or female (sex assigned at birth, inclusive of all gender identities).
  • Age 18 years or above at the time of signing the informed consent.
  • Body mass index (BMI) greater than or equal to (>=) 30.0 kilogram per square meter (kg/m^2) at screening.
  • Participant must have a desire and be committed to lose at least 25 percentage (%) of their body weight from randomisation.

Key exclusion criteria

  • Known or suspected hypersensitivity to study intervention(s) or related products.
  • Treatment with any medication prescribed for the indication of obesity or weight management (e.g. glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues)) within 90 days before screening.
  • Glycated haemoglobin (HbA1c) >= 6.5% (48 Millimoles per mole [mmol/mol]) as measured by the central laboratory at screening.
  • History of type 1 or type 2 diabetes mellitus.

Where this study is enrolling

This trial has 24 sites across 17 states. Contact a site coordinator directly to start screening.

Alabama1 site
  • Chambliss Clinical Trials, LLC
    Montgomery, Alabama
California2 sites
  • FDRC
    Costa Mesa, California
  • Los Angeles Institute for Metabolic Research
    Los Angeles, California
Florida3 sites
  • Encore Medical Research LLC
    Hollywood, Florida
  • South Broward Research LLC
    Miramar, Florida
  • West Orange Endocrinology
    Ocoee, Florida
Illinois2 sites
  • Cedar-Crosse Research Center
    Chicago, Illinois
  • Great Lakes Clinical Trials
    Chicago, Illinois
Indiana1 site
  • Midwest Inst For Clin Res
    Indianapolis, Indiana
Kentucky1 site
  • L-MARC Research Center
    Louisville, Kentucky
Maryland1 site
  • Endo And Metab Cons
    Rockville, Maryland
Missouri1 site
  • StudyMetrix Research LLC
    City of Saint Peters, Missouri
New York1 site
  • Great Lakes Medical Research
    Westfield, New York
North Carolina1 site
  • KDCILM, LLC & Accellacare US, Inc.
    Wilmington, North Carolina
Ohio1 site
  • Family Practice Center of Wadsworth Inc.
    Wadsworth, Ohio
Pennsylvania1 site
  • UPA Ctr Weight and Eating Dis
    Philadelphia, Pennsylvania
Rhode Island1 site
  • Clinical Res Collaborative
    Cumberland, Rhode Island
Tennessee3 sites
  • Holston Medical Group_Bristol
    Bristol, Tennessee
  • Holston Medical Group
    Kingsport, Tennessee
  • Clinical Research Associates
    Nashville, Tennessee
Texas2 sites
  • PlanIt Research, PLLC
    Houston, Texas
  • Pinnacle Clinical Research
    San Antonio, Texas
Virginia1 site
  • National Clin Res Inc.
    Richmond, Virginia
Washington1 site
  • Rainier Clin Res Ctr Inc
    Renton, Washington

Timeline

Started enrolling: 2026-06-09. Expected completion: 2027-07-12. Last updated on ClinicalTrials.gov: 2026-07-10.

Official source

We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact
Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.